



















Indirect and circumstantial clinical evidence suggests 
that metastasis often occurs early in tumor progression. 
In early stage breast cancer, for example, a significant 
percentage of patients exhibit circulating tumor cells 
(CTC’s) and disseminated bone marrow tumor cells 
(DTC’s) [1,2]. More direct experimental evidence for 
“early metastasis” has been observed in studies of 
transgenic mice expressing a cancer-causing oncogene 
where the primary cancer early on exists in an “in situ” 
stage yet bone marrow metastases are discovered [3]. If 
metastasis indeed occurs early, then the rate-limiting 
steps which give rise to metastasis must also occur 
early. Some rate-limiting steps include both 
angiogenesis as well as lymphangiogenesis. However 
there have been alternate short-circuiting mechanisms 
proposed for these phenomenon including vasculogenic 
mimicry [4]. Another key rate-limiting step in the 
metastatic process is tumoral embolic formation within 
lymphovascular channels. The canonical view of the 
origin of tumor lymphovascular emboli is that they 
directly originate from lymphovascular invasion. We 
found evidence, however that tumoral lymphovascular 
emboli can result from the short-circuiting step of 
encircling lymphovasculogenesis [5]. Experimentally, 
we used a xenograft of human inflammatory breast 
cancer (MARY-X), a model that exhibited florid tumor 
emboli, to generate tumoral spheroids in vitro. In 
observational studies, we chose human breast 
carcinoma cases where there appeared to be a possible 
transition of in situ carcinoma to lymphovascular 
emboli without intervening stromal invasion. These 
cases were studied by morphometry as well as IHC with 
tumor proliferation (Ki-67) and adhesion (E-cadherin) 





















(podoplanin [D2-40], CD31, VEGFR-3, Prox-1) 
markers. Unlabelled spheroids coinjected with  either                        
GFP or RFP-human myoepithelial cells or murine 
embryonal fibroblasts (MEFs) gave rise to tumors 
which exhibited GFP/RFP immunoreactivity within the 
cells lining the emboli-containing lymphovascular 
channels. In vitro studies demonstrated that the tumoral 
spheroids induced endothelial differentiation of 
cocultured myoepithelial cells and MEFs, measured by 
real time PCR and immunofluorescence. In humans, the 
DCIS clusters exhibited similar proliferation, E-
cadherin immunoreactivity and size as the tumor emboli 
(p =.5), suggesting the possibility that the latter 
originated from the former. The DCIS clusters exhibited 
a loss (50%-100%) of p63 myoepithelial immuno-
reactivity but not E-cadherin epithelial immuno-
reactivity. The tumor emboli were mainly present 
within lymphatic channels whose dual p63/CD31, 
p63/D2-40 and p63/VEGFR-3 and overall weak 
patterns of D2-40/CD31/VEGFR-3 immunoreactivities 
suggested that they represented immature and newly 
created vasculature derived from originally myo-
epithelial-lined ducts. Collectively both experimental as 
well as observational studies suggested the possibility 
that these breast cancer emboli resulted from encircling 
lymphovasculogenesis rather than conventional 
lymphovascular invasion. Encircling lymphovasculo-
genesis as the mechanism of lymphovascular invasion 
represents a paradigm shift in our thinking about this 
phenomenon. The lymphovascular embolus represents 
the phenomenon of the “ship in the bottle” where the 
arduous and complex task of constructing a ship within 
a bottle is replaced with the relatively effortless and 
simple job of building the bottle around the ship [5].  
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